Obesity Clinical Trials in Baltimore, Maryland

12 studies are recruiting for obesity in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Ascension Saint Agnes Heart Care, Baltimore, Maryland

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

   The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which tre…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   PAREXEL Intl - EPCU-Baltimore, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07566390 on ClinicalTrials.gov

3. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ascension Saint Agnes Heart Care, Baltimore, Maryland

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

4. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Ascension Saint Agnes Heart Care, Baltimore, Maryland

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

5. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide …

   Stage

   Phase 3

   Ages

   8 to 18

   Site

   Barry J. Reiner, MD LLC, Baltimore, Maryland

   Locations

   121 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07253285 on ClinicalTrials.gov

6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Johns Hopkins Children's Center, Baltimore, Maryland

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

7. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

   The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Good Samaritan Hospital, Baltimore, Maryland

   Locations

   162 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07321886 on ClinicalTrials.gov

8. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ascension Saint Agnes Heart Ca, Baltimore, Maryland

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

9. Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure

   This study aims to determine whether a 6-month multilevel intervention involving problem-solving training, exercise training and support from community health workers is more effective in improving outcomes for individuals with low socioeconomic status, type 2 diabetes, obesity, and early cardiac d…

   Stage

   Not phased

   Ages

   30 to 70

   Site

   Johns Hopkins Center for Health Equity, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Johns Hopkins University

   See if you can join NCT06364644 on ClinicalTrials.gov

10. Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation

    The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention…

    Stage

    Not phased

    Ages

    Up to 80

    Site

    Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland

    Locations

    2 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT05880108 on ClinicalTrials.gov

11. Health Promotion With Targeted Exercise Intervention for Decreasing Fall Risk and Inactivity in Aging Veterans With Obesity and Signs of Sarcopenia

    Falls are a major health risk for older Veterans, especially those with both obesity and low muscle mass or strength (sarcopenia), which together increase the chances of falling and losing independence. Many older Veterans have difficulty staying active and often lack information about how to safel…

    Stage

    Not phased

    Ages

    55 and older

    Site

    Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland

    Run by

    VA Office of Research and Development

    See if you can join NCT07206368 on ClinicalTrials.gov

12. Dinner Time for Obesity and Prediabetes

    Obesity and its metabolic complications are leading causes of global morbidity and mortality. Evidence is mounting that inappropriate timing of food intake contributes to obesity. Specifically, late eating is associated with greater weight gain and metabolic syndrome. However, the mechanism by whic…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    Johns Hopkins Bayview Medical Center, Baltimore, Maryland

    Locations

    2 in total

    Run by

    Johns Hopkins University

    See if you can join NCT05745441 on ClinicalTrials.gov